ow Dose Radiotherapy for COVID-19 Pneumonia using a Linear accelerator: Proposal for a prospective trial

Guru Hospitals0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Patients with confirmed diagnosis of SARS-Cov2 infection by RT-PCR on nasopharyngeal swab and / or bronchoalveolar lavage (BAL)
•2.moderate to severe dyspnoea, respiratory frequency >= 30/min, oxygen saturation with supplemental O2 supply (SpO2) < 92%, PaO2/FiO2 ratio or PaFiO2 ratio between 200 to 300 or SpO2/FiO2 ratio < 315 if PaO2 is not available
•3.laboratory abnormalities such as C-reactive protein (CRP) >100 mg/L, D-dimer >1000 ng/ml, IL-6 >40 IU or suspected cytokine release syndrome.
•4.first and second criteria are mandatory and third is optional

•1.Prior lobectomy or pneumonectomy
•2.contraindication to radiation (Example: Known hereditary syndrome with increased sensitivity to ionizing radiation, e.g., ataxia-telangiectasia or Fanconi anemia)
•3.previous history of radiation to thoracic organs
•4.Prior chemotherapy or other systemic therapy with potential for pulmonary toxicity or radio sensitization within 14 days or 5 half-lives, whichever is greater, of enrollment, e.g., bleomycin, gemcitabine
•5.Severe pre-existing heart disease, e.g., New York Heart Association (NYHA) functional class >= 3 congestive heart failure
•6.Pregnancy.

发起方

Guru Hospitals